UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Soleno Therapeutics, Inc.

(Name of Issuer)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)

834203200

(CUSIP Number)

Jack W. Schuler

100 N. Field Drive, Suite 360

Lake Forest, Illinois 60045

(224)-880-1210

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 21, 2019

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box:  ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 834203200

CUSIP No. 834203200

Explanatory Note

This Amendment No. 3 (this “Amendment”) amends and supplements the Schedule 13D filed on January 12, 2018, Amendment No. 1 to Schedule 13D filed December 10, 2018, and Amendment No. 2 to Schedule 13D filed January 3, 2019 (collectively, the “Original Schedule 13D”) by Jack W. Schuler Living Trust and other entities relating to the Common Stock of Soleno Therapeutics, Inc. (the “Issuer”). This Amendment combines in one filing three Schedule 13D/A amendments and reports all disclosure that would have been required in each amendment had they been timely filed. Information reported in the Original Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Original Schedule 13D. All references in the Original Schedule 13D and this Amendment shall be deemed to refer to the Original Schedule 13D as amended and supplemented by this Amendment.

Item 1. Security and Issuer.

Item 1 is amended and restated in its entirety to read as follows:

The class of equity securities to which this Schedule 13D relates is the Common Stock, par value $0.001 per share (the “Common Stock”), of Soleno Therapeutics, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 203 Redwood Shores Pkwy, Suite 500, Redwood City, CA 94065.

Item 2. Identity and Background.

Item 2 is amended and restated in its entirety to read as follows:

(a-c, f). This Schedule 13D is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)¹:

100 N. Field Drive, Suite 360

Lake Forest, Illinois 60045

100 N. Field Drive, Suite 360

Lake Forest, Illinois 60045

Jack W. Schuler is a citizen of the United States, and is principally engaged in the business of investing in securities. Mr. Schuler serves as sole trustee to the Living Trust, a living trust established by Mr. Schuler. In such capacity, Mr. Schuler may be deemed to beneficially own the shares held by the Living Trust.

Jack W. Schuler serves as President of the Foundation. In such capacity, Mr. Schuler may be deemed to beneficially own the shares held by the Foundation.

(d) Neither Jack W. Schuler nor any of the Reporting Persons, has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) Neither Jack W. Schuler nor any the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 is amended and restated in its entirety to read as follows:

2017 Purchase Agreement

On December 11, 2017, the Issuer entered into a securities purchase agreement with the Living Trust and certain other institutional and accredited investors (the “2017 Purchase Agreement”). Pursuant to the terms of the 2017 Purchase Agreement, the Issuer agreed to issue and sell its shares of Common Stock (the “Shares”) in a private placement, at $1.8425 per share. Each Share was issued with a warrant to purchase 0.74 additional Shares at an exercise price of $2.00 per share (each, a “2017 Warrant”). The Living Trust purchased 1,519,676 Shares and a 2017 Warrant to purchase 1,124,560 Shares.

A total of $2,800,003.03 was paid to acquire the Shares and a 2017 Warrant by the Living Trust in connection with the 2017 Purchase Agreement. The source of the funds for such acquisitions by the Living Trust was working capital. No part of the purchase price was borrowed by the Living Trust for the purpose of acquiring such securities.

2018 Purchase Agreement

On December 19, 2018, the Issuer entered into a Securities Purchase Agreement with the Living Trust and certain other institutional and accredited investors (the “2018 Purchase Agreement”). Pursuant to the terms of the 2018 Purchase Agreement, the Issuer agreed to issue and sell units in a private placement, at $1.60625 per unit (each, a “Unit”). Each Unit contained one Share at a purchase price of $1.60, which was the closing price of the Issuer’s Shares on the day immediately preceding the date of the 2018 Purchase Agreement, and a warrant to purchase 0.05 additional Shares at a purchase price of $0.00625 (each, a “2018 Warrant”). Each 2018 Warrant has an exercise price of $2.00 per Share. The Living Trust purchased 3,031,002 Shares and a 2018 Warrant to purchase 151,550 Shares.

A total of $4,868,546.97 was paid to acquire the Shares and a 2018 Warrant by the Living Trust in connection with the 2018 Purchase Agreement. The source of the funds for such acquisitions by the Living Trust was working capital. No part of the purchase price was borrowed by the Living Trust for the purpose of acquiring such securities.

2019 Open Market Purchases

Between March 21, 2019 and May 20, 2019, the Foundation purchased on the open market an aggregate of 835,717 shares of Common Stock of the Issuer at weighted-average purchase prices ranging from $1.9285 to $2.3716 per share (collectively, the “2019 Open Market Purchases”). The source of funds for such acquisitions by the Foundation was working capital. No part of the purchase price was borrowed by the Foundation for the purpose of acquiring such securities

2019 Public Offering

Pursuant to a firm-commitment underwritten public offering of shares of the Issuer’s Common Stock that closed on October 25, 2019 (the “2019 Public Offering”), the Living Trust purchased 1,666,667 shares of Common Stock at a per share purchase price of $1.20. The source of funds for such acquisition by the Living Trust was working capital.

Pursuant to the 2019 Public Offering, the Foundation purchased 897,083 shares of Common Stock at a per share purchase price of $1.20. The source of funds for such acquisition by the Foundation was working capital.

No part of the purchase price was borrowed by the Living Trust or the Foundation for the purpose of acquiring such securities

2020 Public Offering

Pursuant to a firm-commitment underwritten public offering of shares of the Issuer’s Common Stock that closed on June 26, 2020 (the “2020 Public Offering”), the Living Trust purchased 5,151,517 shares of Common Stock at a per share purchase price of $1.65. The source of funds for such acquisition by the Living Trust was working capital.

Pursuant to the 2020 Public Offering, the Foundation purchased 2,424,242 shares of Common Stock at a per share purchase price of $1.65. The source of funds for such acquisition by the Foundation was working capital.

No part of the purchase price was borrowed by the Living Trust or the Foundation for the purpose of acquiring such securities

Item 4. Purpose of Transaction.

Item 4 is amended and restated in its entirety to read as follows:

The response to Item 3 is incorporated herein by reference.

The descriptions and summaries of the 2017 Purchase Agreement, the 2017 Warrants, the 2018 Purchase Agreement and the 2018 Warrants set forth in Item 3 do not purport to be complete and are qualified in their entirety by reference to the full text of the 2017 Purchase Agreement, the form of 2017 Common Stock Purchase Warrant, the 2018 Purchase Agreement and the form of 2018 Common Stock Purchase Warrant, which are included as Exhibit 2, Exhibit 3, Exhibit 4 and Exhibit 5, respectively, and are incorporated herein by reference.

The description and summary of the 2019 Open Market Purchases set forth in Item 3 does not purport to be complete and is qualified in its entirety by reference to information pertaining to the 2019 Open Market Purchases set forth in Item 5.

The descriptions and summaries of the 2019 Public Offering and the 2020 Public Offering set forth in Item 3 do not purport to be complete and are qualified in their entirety by reference to the Section 424(b)(5) Prospectus Supplement pertaining to the 2019 Public Offering filed October 24, 2019 and the Section 424(b)(5) Prospectus Supplement pertaining to the 2020 Public Offering filed June 25, 2020, respectively, and are incorporated herein by reference and available by accessing our filings on the SEC’s website at www.sec.gov.

All securities referenced in Item 3 were acquired by the Living Trust and by the Foundation for investment purposes only.

Item 5 is amended and restated to read in its entirety as follows:

(a, b) The responses of the Living Trust and the Foundation to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Amendment are incorporated herein by reference. As of the close of business on July 16, 2020, (i) the Living Trust beneficially owned 12,644,972 shares of Common Stock, representing approximately 15.65% of the outstanding shares of Common Stock of the Issuer and (ii) the Foundation beneficially owned 4,157,042 shares of Common Stock, representing approximately 5.23% of the outstanding shares of Common Stock of the Issuer. The percentages in this paragraph are calculated based on 79,535,365 shares of Common Stock of the Issuer, which is the total number of shares of Common Stock of the Issuer outstanding as of June 26, 2020, based on 44,686,881 outstanding shares referenced in the Section 424(b)(5) Prospectus Supplement filed June 25, 2020 with the Securities and Exchange Commission (the “SEC”), plus 34,848,484 shares sold to underwriters of the Issuer’s public offering on June 26, 2020, as set forth in a Current Report on Form 8-K filed with the SEC on June 26, 2020.

As sole trustee of the Living Trust, Jack W. Schuler and the Living Trust share the power to vote or to direct the vote, and the power to dispose or to direct the disposition of, the shares held by the Living Trust. As President of the Foundation, Jack W. Schuler and the Foundation share the power to vote or to direct the vote, and the power to dispose or to direct the disposition of, the shares held by the Foundation.

(c) The following table sets forth the 2019 Open Market Purchases that should have been reported in the first of the three required Schedule 13D amendments:

The following table sets forth purchases pursuant to the 2019 Public Offering that should have been reported in the second of the three required Schedule 13D amendments:

The following table sets forth purchases pursuant to the 2020 Public Offering that should have been reported in the third of the three required Schedule 13D amendments:

Item 6 is amended and restated to read in its entirety as follows:

The responses set forth in Item 3 and Item 4 are incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Soleno Therapeutics, Inc. dated as of July 16, 2020 is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.